Skip to main content
Premium Trial:

Request an Annual Quote

Fluorotechnics' Q1 Revenues Drop to $224K

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Australian fluorescence and protein detection technologies firm Fluorotechnics last week reported revenues from customers for the first quarter of A$204,346 (US$224,006), down nearly nine-fold from A$1.8 million a year ago.

The company, which is in the middle of a turnaround effort, also reported net operating cash flows came in at a loss of A$273,609 for the three months ended March 31, compared to a loss of A$1.5 million a year ago.

R&D costs were sliced to A$20,813 from A$254,80,6 and SG&A costs shriveled to A$7,667 from A$353,608 a year ago.

As part of its effort to stay afloat, Fluorotechnics sold its US subsidiary Gel Company for $150,000 in October, and its gel and High Performance Electrophoresis, or HPE, Tower technology in December.

In a letter accompanying the release of its Q1 earnings results, Ian Gilmour, company secretary, said that Fluorotechnics continues to scale back its operations and sell off assets, and the company's ongoing cash burn has been "significantly reduced."

Fluorotechnics is evaluating new investment opportunities, Gilmour added.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.